肌醇 Inositol × 多囊性卵巢症候群

結論:證據支持但有警示

Multiple RCTs and meta-analyses consistently show myo-inositol significantly improves metabolic and androgenic surrogate markers in PCOS (fasting insulin SMD -1.

B 🟡 B 初步證據 附警語發布 ⚠️ medium — moderate promotional content
⚠️ 標記 ⚠️ COI(產業聯盟資助) 🇹🇼 台灣在地警示

Multiple RCTs and meta-analyses consistently show myo-inositol significantly improves metabolic and androgenic surrogate markers in PCOS (fasting insulin SMD -1.02, HOMA index SMD -0.59, SHBG rise with >=24 weeks of use), and a 2025 meta-analysis reports a clinical pregnancy benefit in the ART setting (RR 1.64). However, the hard reproductive endpoint of live birth rests on very low quality evidence: the 2018 Cochrane review found a non-significant OR 2.42 (95% CI 0.75-7.83) from only 2 trials and 84 women, and the 2024 systematic review informing the 2023 International PCOS Guideline graded all androgenic, metabolic and reproductive outcomes as low certainty due to small samples, risk of bias and imprecision. The 2023 International Evidence-based PCOS Guideline (co-endorsed by ASRM) gives only a conditional could-be-considered recommendation, prefers metformin for hirsutism and central adiposity, and declines to recommend any specific inositol type or dose. Examine's grade A reflects a composite PCOS Symptoms surrogate/symptom outcome rather than hard reproductive endpoints, so it overstates the certainty for the clinically meaningful question. The totality is moderate, consistent benefit on surrogate metabolic measures but genuine uncertainty on hard outcomes, which is a solid B rather than an A.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.65
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
81%
證據方向一致性高
證據層級
E1
Cochrane 高品質系統性回顧/統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.65
L5 臨床機構權威立場
0.67
L2 PubMed原始文獻
0.70
L3 機轉生理合理性
0.75
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.646
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines
PMID: 38163998 2024 統合分析 n = 2,230
結論:Across 30 RCTs (19 in meta-analyses), D-chiro-inositol showed low-certainty benefits for SHBG, DHEAS, AUC glucose and AUC insulin versus placebo, with a potential ovulation benefit (OR 11.5, low quality); myo-inositol effects on HOMA-IR were inconclusive and reproductive outcomes likely showed no difference versus metformin. All outcomes were graded low certainty due to small samples, risk of bias and imprecision.
效應量:DCI ovulation OR 11.5 (low certainty); MI HOMA-IR inconclusive
前往 PubMed
Inositol for subfertile women with polycystic ovary syndrome (Cochrane Database of Systematic Reviews)
PMID: 30570133 2018 Cochrane SR n = 1,472
結論:Across 13 RCTs the authors were uncertain whether myo-inositol improves live birth (OR 2.42, 95% CI 0.75-7.83; very low-quality evidence, only 2 trials / 84 women) or clinical pregnancy rate (OR 1.27, 95% CI 0.87-1.85; very low-quality evidence). A possible miscarriage reduction was unreliable due to heterogeneity. Conclusions were cautious: no high-quality evidence supports current clinical practice.
🟢 高品質 政府資助 效應量:Live birth OR 2.42 (95% CI 0.75-7.83), very low quality; clinical pregnancy OR 1.27 (95% CI 0.87-1.85)
前往 PubMed
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
PMID: 29042448 2017 統合分析 n = 496
結論:Myo-inositol significantly decreased fasting insulin (SMD -1.021 uU/mL, 95% CI -1.791 to -0.251, p=0.009) and HOMA index (SMD -0.585, 95% CI -1.145 to -0.025, p=0.041). Serum SHBG rose significantly only when MI was given for at least 24 weeks (SMD 0.425 nmol/L, 95% CI 0.050-0.801, p=0.026). Testosterone showed a non-significant downward trend.
效應量:Fasting insulin SMD -1.02; HOMA SMD -0.59; SHBG SMD +0.43 (>=24 wk only)
前往 PubMed
The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies
PMID: 40989082 2025 統合分析
結論:Myo-inositol increased clinical pregnancy rate by 64% (RR 1.64, 95% CI 1.25-2.15) and top-grade embryos by 12% (RR 1.12, 95% CI 1.02-1.23), with a slightly higher metaphase II oocyte count (WMD +0.28) but essentially no change in total oocytes retrieved. A reduction in antral follicle count and anti-Mullerian hormone was noted with supplementation.
效應量:Clinical pregnancy RR 1.64; top-grade embryos RR 1.12
前往 PubMed

L4a US FDA
中性
Inositol is recognized as Generally Recognized As Safe (GRAS) for use as a nutrient supplement; affirmed under 21 CFR 184.1370. 來源↗
L4b EU EFSA
中性
L4c UK NHS
中性
A commercially available supplement called Inofolic, which is a combination of Myo Inositol and folic acid, has shown benefit in initial studies to improve the metabolic defect in PCOS and make menstrual cycles more regular. 來源↗
L4d TW TFDA / 衛福部
中性
嬰兒配方食品及較大嬰兒配方輔助食品之檢驗值應符合中華民國國家標準(CNS)所定之標準。 來源↗
L4e WHO
中性
Minimum 4 mg/100 kcal of myo-inositol; Guidance Upper Level (GUL) 40 mg/100 kcal. [Codex Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants, CODEX STAN 72-1981] 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
支持
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

好孕板與 Dcard 大量討論,多囊備孕族群普遍正面回報月經/排卵改善,視為養卵保健標配;但本質仍是個人經驗,非研究證據。

💬社群實感

多數正面(限多囊備孕族群,回報月經規律化與成功懷孕;非多囊使用者多認為無效)

破解迷思 社群最常見的 4 個誤解
迷思「肌醇人人可吃、有助卵子品質」
事實社群多人澄清非多囊者吃通常無效
迷思「吃肌醇就不能/不需併用 DHEA 或 Metformin」
事實醫師實際常依個案併用或擇一
迷思「Metformin 不能長期吃」
事實醫師多開長期處方,停用常是健保不給付而非安全問題
迷思把『懷孕』直接歸功於肌醇
事實多為合併調理與時間因素的事後歸因
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • NOW Foods 肌醇
  • BHK's
  • GNC
  • 好韻(含葉酸複方)
  • 活力媽媽(肌醇+葉酸)
  • 英國助孕維他命

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

倍韻肌醇每顆含肌醇480毫克、葉酸100微克、維他命D3,一盒60顆售價NT$789元;建議肌醇每日用量1200~4000毫克

代表來源 ↗
L10b · TFDA 法定身份 官方認定

食品廣告若涉及不實、誇張或易生誤解,可處新臺幣4萬元以上400萬元以下罰鍰;涉及醫療效能者,可處60萬元以上500萬元以下罰鍰

來源 ↗

  • 健康生活型態與體重管理
  • 複方口服避孕藥
  • Metformin(二甲雙胍)
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v25 engine_version: v1.0 claim_id: CLM-COND-pcos-INT-inositol-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-pcos-INT-inositol-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "肌醇能改善多囊性卵巢症候群",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 3,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟡 B 初步證據"
  }
}